




DRUG DISCOVERY

## **The Emerging Role of Postmarketing Clinical Research**

Regulatory issues, strategic drivers and overall trends

By Isabel Fraser-Moodie

 **Table of Contents**

## **Isabel Fraser-Moodie**

Isabel Fraser-Moodie is an analyst within the healthcare practice of Business Insights. She has previously worked in the competitive intelligence function for different pharmaceutical corporations. Her areas of interest are drug discovery, R&D innovation and science policy, specifically related to commercialization of new medical innovations. Isabel graduated with a Master's degree in Natural Sciences from Cambridge University, where she specialized in legislation targeting emerging genetic therapeutics and diagnostics.

Copyright © 2008 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The Emerging Role of Postmarketing Clinical Research

<b>Executive Summary</b>	<b>8</b>	
Background to postmarketing research	8	
Mandatory postmarketing trial requirements	8	
Phase IV trials for market development	10	
Impact of competitive pressures and pipeline strength on phase IV trials	11	
Appropriate trial design	12	
<b>Chapter 1</b>	<b>Background to postmarketing research</b>	<b>16</b>
Summary		16
Introduction		17
The clinical trial landscape		19
Priorities and end-points in clinical development		20
Safety and full market approval		22
Health-economic arguments		23
Life cycle management		23
Product positioning and differentiation		23
<b>Chapter 2</b>	<b>Mandatory postmarketing trial requirements</b>	<b>28</b>
Summary		28
FDA regulations for postmarketing trials		29
Postmarketing commitment trials (PMC)		29
Direct and indirect drivers for PMC conduct		33
Indirect driver: Public health priorities		33
Direct driver: Orphan drugs		34
PMC Case Study: Iressa		35
PMC Case study: Vioxx		37

Postmarketing surveillance studies (PMS)	38
PMS study drivers	39
PMS design limitations	39
FDA Amendment Act (FDAAA)	42
Industry implications of FDAAA	43
Public submission of datasets	43
<b>EMEA</b>	<b>45</b>
Terms of marketing approval agreement	45
<b>Joint FDA-EMEA drug monitoring initiatives</b>	<b>45</b>
<b>Trials for improved clinical guidance</b>	<b>47</b>

## **Chapter 3                      Phase IV trials for market development                      50**

<b>Summary</b>	<b>50</b>
<b>Introduction</b>	<b>51</b>
<b>Phase IV trials for formulary access</b>	<b>54</b>
US – the importance of comparative effectiveness	56
EU – the importance of added therapeutic value	58
<b>Postmarketing trials for indication expansion</b>	<b>59</b>
The Rx to OTC switch	62
Off-label physician use and risk management	64
Product development for indication expansion	66
Line extensions	68
Case Study: Line extension launch profiles	68
Case study: Zoloft (sertraline)	69
Reformulations	71
Follow-on compounds	71
Phase IV trials for multiple indication expansion strategies	71
Case study: Zyprexa	72
Case study: Alimta (Pemetrexed)	74
<b>Enhanced market positioning</b>	<b>77</b>
Marketing regulations	77
Head to Head trials	78
Case study: Zyprexa vs Risperdal	79
US Direct to Consumer (DTC) regulations	80
EU marketing regulations	80
<b>Influence of sponsorship on trial endpoint</b>	<b>81</b>
Impact of budget constraints	82
Big pharmaceutical firms	83
Mid tier biopharma and biotechnology firms	83
<b>Big pharma’s scale advantage</b>	<b>85</b>
Case study: Novartis	86
Case study: Glivec (Imatinib mesylate)	88

	Case study: Aclasta (zoledronic acid)	89
	<b>Misuse of phase IV trials and regulator scrutiny</b>	<b>90</b>
<b>Chapter 4</b>	<b>Impact of competitive pressures and pipeline strength on phase IV trials</b>	<b>94</b>
	Summary	94
	<b>The impact of competition</b>	<b>95</b>
	Market scenario: Cardiovascular	97
	Case study: Diovan	99
	Market scenario: oncology	100
	Antineoplastics - market drivers for phase IV trials	102
<b>Chapter 5</b>	<b>Effective phase IV trial design</b>	<b>106</b>
	Summary	106
	<b>Introduction</b>	<b>107</b>
	<b>Endpoint designation and trial purpose</b>	<b>107</b>
	<b>Patient and physician recruitment</b>	<b>108</b>
	Recruitment bottlenecks	110
	<b>Design limitations</b>	<b>110</b>
	Study design	112
	<b>Data management and adaptive clinical trial designs</b>	<b>113</b>
	Operational management	114
<b>Chapter 6</b>	<b>Appendix</b>	<b>117</b>
	Primary research methodology	117
	Glossary	118
	Index	120

# List of Figures

Figure 2.1: Projected R&D spend by phase 2005-2009 (\$bn),	19
Figure 2.2: Postmarketing research and product lifecycle	20
Figure 3.3: NDA and ANDA requirements for postmarketing status reports	31
Figure 3.4: Biological product reporting requirements for postmarketing status reports	32
Figure 3.5: Sales of Iressa in the US, 2003-2007 (\$m)	36
Figure 3.6: Vioxx sales in the US, 2003-2004 (\$m)	38
Figure 3.7: Implication of FDA requirement of REMS	41
Figure 3.8: Implications of tightened FDA policies	43
Figure 4.9: Market drivers for postmarketing research	51
Figure 4.10: Declining return on R&D investment (US, 1990-2004)	52
Figure 4.11: Payor's influence gain in prescribing decisions; US market, share of voice, 2007	56
Figure 4.12: Marketing and product development strategies using phase IV trials	60
Figure 4.13: Phase IV for product lifecycle management	62
Figure 4.14: Sales summary for Zoloft in the US, 2000-2006	70
Figure 4.15: Use of postmarketing trials for lifecycle management of Zyprexa, US and EU5, 2000-2007 (\$m)	73
Figure 4.16: Effect of indication expansion on sales of Alimta in the US, 2004-2007 (\$m)	76
Figure 4.17: Big pharma phase IV trials by strategic purpose, USA, 1998-2007	86
Figure 4.18: Number of phase IV trials by different 'Big pharma' companies	87
Figure 5.19: Impact of market competition on phase IV trial design and objective	95
Figure 5.20: Global cardiovascular product pipeline, Q1 2008	98
Figure 5.21: Diovan sales in the US, 1998-2007 (\$m)	100
Figure 5.22: Global cancer product pipeline, Q1 2008	101
Figure 5.23: Number of phase IV trials vs sales growth, USA, 2003-2007	103
Figure 6.24: Factors influencing successful Phase IV conduct	107
Figure 6.25: Advantages and disadvantages posed by phase IV study designs	112

# List of Tables

Table 2.1: Phase IIIb vs Phase IV postmarketing studies	18
Table 4.2: On-label indication expansion drivers	67
Table 4.3: Declining incremental sales revenue return with subsequent line extension launches	69
Table 4.4: Zyprexa- Pivotal phase IV trials for indication expansion and formulary access	74
Table 4.5: Industry vs non-industry trial objectives	82
Table 4.6: Trial characteristics by commissioning organization, 1998-2008*	85
Table 6.1: Influence of study participation on subsequent drug prescribing	109
Table 6.2: Advantages and disadvantages of using adaptive clinical trial designs	114